Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051272 · ClinicalTrials.gov registry record · Phase 3
Effects Of Antidepressants On Sexual Functioning In Adults
A Phase 3 study of Major Depressive Disorder (MDD), sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 425
- Enrollment target
- 20
- Study locations
NCT00051272: Completed Phase 3 study of Major Depressive Disorder (MDD), sponsored by GlaxoSmithKline.
NCT00051272 is a Phase 3 study of Major Depressive Disorder (MDD) that has completed, run by GlaxoSmithKline. The registered enrollment target is 425 participants, above the 139-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (206% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051272, a Phase 3 study of Major Depressive Disorder (MDD), has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 425 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the effects of two antidepression medications on sexual functioning.
Conditions Studied
Interventions
- DRUG Extended-release Bupropion Hydrochloride
Study Locations (20)
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Scottsdale
Georgia
- GSK Investigational Site - Marietta
- GSK Investigational Site - Smyrna
Texas
- GSK Investigational Site - Bellaire
- GSK Investigational Site - San Antonio
California
- GSK Investigational Site - Berkeley
Connecticut
- GSK Investigational Site - Middletown
Delaware
- GSK Investigational Site - Wilmington
District of Columbia
- GSK Investigational Site - Washington D.C.
Florida
- GSK Investigational Site - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
What the finished NCT00051272 record still lists
NCT00051272 is an interventional study that assigns participants to a tested intervention. The registered 425 participants enrollment target is mid-sized for trials with a published cap, above the 139-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (206% higher).
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 1 intervention - of which Extended-release Bupropion Hydrochloride is the first listed.
NCT00051272 names 20 study sites across 17 states, led by Arizona, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT00051272 about?
NCT00051272 is a clinical study titled "Effects Of Antidepressants On Sexual Functioning In Adults". This study will evaluate the effects of two antidepression medications on sexual functioning.
What is the current status of trial NCT00051272?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 425 participants. The study started on 2003-01. Estimated completion is 2004-06.
What conditions does trial NCT00051272 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT00051272?
The interventions under investigation include: Extended-release Bupropion Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00051272?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051272 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00051272's enrollment target sits among peer trials
425 2nd of 22 the highest of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
RECRUITING · Phase 3
-
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
COMPLETED · Phase 3
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Neurofeedback to Treat Depression - 2
RECRUITING · NA
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
- NCT05340738 · 425 participants · NA
AI-Based Fidelity Feedback to Enhance CBT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia